Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Fondation Transplantation_EDDH | UNKNOWN |
| Hopital Lariboisière | OTHER |
| Cliniques universitaires Saint-Luc- Université Catholique de Louvain | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this prospective study is to assess the prognostic value of bioactive plasma adrenomedullin (ADM) in 600 patients with severe sepsis or septic shock in an international multicenter study and to validate the findings concerning the association of ADM concentration and the use of vasopressor therapy, organ failure and outcome.
Sepsis involves an overactive inflammatory response to severe bacterial infection that can compromise vascular integrity and cause tissue edema, organ dysfunction and death. Adrenomedullin (ADM) has attracted the interest of researchers because of its powerful physiological functions. An anti-ADM antibody reduced the norepinephrine infusion rates required to achieve hemodynamic targets, increased urine flow and improved creatinine clearance, which ultimately resulted in attenuated systemic inflammation and tissue apoptosis, during resuscitated cecal ligation and puncture (CLP)-induced septic shock in mice.
In humans, plasma ADM has been determined only in a small number of sepsis patients, and - except from one study - the assays used did not selectively measure the bioactive ADM form and have been considered not reliable. Therefore, the potential value of determining plasma ADM in such patients cannot yet be ascertained and the optimal cut off needs to be validated in future studies
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| rate of all-cause mortality | Day 28. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
600 patients admitted in intensive care unit of 26 hospitals, in 5 countries, with diagnosis of severe sepsis or septic shock, will be included in this study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alexandre Mebazaa, Pr | Hôpital Lariboisière, France | Principal Investigator |
| Pierre François Laterre, Pr | Clinique Universitaire St Luc, Belgique | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cliniques Universitaires Saint-Luc | Brussels | 1200 | Belgium | |||
| CH Jolimont |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34282296 | Derived | Jolly L, Carrasco K, Salcedo-Magguilli M, Garaud JJ, Lambden S, van der Poll T, Mebazaa A, Laterre PF, Gibot S, Boufenzer A, Derive M. sTREM-1 is a specific biomarker of TREM-1 pathway activation. Cell Mol Immunol. 2021 Aug;18(8):2054-2056. doi: 10.1038/s41423-021-00733-5. Epub 2021 Jul 19. No abstract available. | |
| 33588925 | Derived |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D018805 | Sepsis |
| D012772 | Shock, Septic |
| ID | Term |
|---|---|
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
Plasma samples without DNA Blood samples (heparin-, EDTA-, EDTA/aprotinin plasma) and urine samples will be collected at the admission, day 2, day 3 and the day of discharge for measuring ADM and other markers
| La Louvière |
| 7100 |
| Belgium |
| Clinique St Pierre | Ottignies | 1340 | Belgium |
| Centre Hospitalier d'Angers | Angers | 49933 | France |
| Centre Hospitalier d'Angoulême | Angoulême | 16959 | France |
| Hopital Estaing | Clermont-Ferrand | 63003 | France |
| Hôpital Louis Mourier, | Colombes | 92700 | France |
| CHD de la Vendée | La Roche-sur-Yon | 85000 | France |
| CHU Dupuytren | Limoges | 87042 | France |
| Hôpital St Louis | Paris | 75010 | France |
| Hôpital Bichat Claude-Bernard | Paris | 75018 | France |
| Hôpital Lariboisière | Paris | France |
| Nouvel Hôpital Civil | Strasbourg | 67000 | France |
| Hôpital de Hautepierre | Strasbourg | 67098 | France |
| CHRU Tours | Tours | 37044 | France |
| Klinik für Operative Intensivmedizin und Intermediate Care | Aachen | Germany |
| Klinikum Augsburg | Augsburg | 86156 | Germany |
| Klinik für Anästhesiologie und Operative Intensivmedizin, Universitätsklinikum Köln | Cologne | 50937 | Germany |
| Klinik für Anästhesie, Intensivmedizin und Schmerztherapie, HELIOS-Klinikum Erfurt, | Erfurt | D99089 | Germany |
| Universitätsklinikum Jena | Jena | 07740 | Germany |
| Azienda Ospedaliera Sant'Andrea | Roma | Italy |
| Policlinico Universitario A. Gemelli | Roma | Italy |
| Medisch Spectrum Twente; Departement of Intensive Care | Enschede | Enschede | 7513 ER | Netherlands |
| UMC Radboudziekenhuis, Dept. Intensive Care | Nijmegen | 6525 | Netherlands |
| Blet A, Deniau B, Santos K, van Lier DPT, Azibani F, Wittebole X, Chousterman BG, Gayat E, Hartmann O, Struck J, Bergmann A, Antonelli M, Beishuizen A, Constantin JM, Damoisel C, Deye N, Di Somma S, Dugernier T, Francois B, Gaudry S, Huberlant V, Lascarrou JB, Marx G, Mercier E, Oueslati H, Pickkers P, Sonneville R, Legrand M, Laterre PF, Mebazaa A; AdrenOSS-1 Study Investigators. Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study. Crit Care. 2021 Feb 15;25(1):61. doi: 10.1186/s13054-021-03471-2. |
| 30583748 | Derived | Mebazaa A, Geven C, Hollinger A, Wittebole X, Chousterman BG, Blet A, Gayat E, Hartmann O, Scigalla P, Struck J, Bergmann A, Antonelli M, Beishuizen A, Constantin JM, Damoisel C, Deye N, Di Somma S, Dugernier T, Francois B, Gaudry S, Huberlant V, Lascarrou JB, Marx G, Mercier E, Oueslati H, Pickkers P, Sonneville R, Legrand M, Laterre PF; AdrenOSS-1 study investigators. Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study. Crit Care. 2018 Dec 21;22(1):354. doi: 10.1186/s13054-018-2243-2. |
| 30450469 | Derived | Hollinger A, Wittebole X, Francois B, Pickkers P, Antonelli M, Gayat E, Chousterman BG, Lascarrou JB, Dugernier T, Di Somma S, Struck J, Bergmann A, Beishuizen A, Constantin JM, Damoisel C, Deye N, Gaudry S, Huberlant V, Marx G, Mercier E, Oueslati H, Hartmann O, Sonneville R, Laterre PF, Mebazaa A, Legrand M. Proenkephalin A 119-159 (Penkid) Is an Early Biomarker of Septic Acute Kidney Injury: The Kidney in Sepsis and Septic Shock (Kid-SSS) Study. Kidney Int Rep. 2018 Aug 22;3(6):1424-1433. doi: 10.1016/j.ekir.2018.08.006. eCollection 2018 Nov. |
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D012769 | Shock |